Seasoned health-care executive joins MedX as Director of International
Business Development
MISSISSAUGA, ON, May 28 /CNW/ - MedX Health Corp. (TSXV: MDX) ("MedX" or the "Company") President, Steve Guillen, announced today the expansion of commercial activities for its low-level laser products internationally, with the appointment of Larry Petersen as the company's Director of International Business Development.
Mr. Petersen will be responsible for developing an international network of distributors for the MedX family of low-level lasers. A recognized industry expert in the sales & marketing of medical devices, Mr. Petersen has developed and launched strategic plans for numerous medical devices internationally, including Europe, Asia, Latin America, and the Middle East. He also has a broad based knowledge of the regulatory and product registration issues and procedures necessary to operate successfully in the wide variety of healthcare systems that exist worldwide.
"Establishing an international distribution system is an important strategic step in our plans for accelerating revenue growth," said MedX President, Steve Guillen. "Mr. Petersen has built highly successful distribution systems for several companies in the past, and he knows exactly what to do, how to do it, and has existing strong distribution relationships in many countries."
Mr. Petersen has over 28 years of experience in Sales & Marketing and International Business Development in a variety of medical device markets. He graduated in the top 5% of his class at the U.S Naval Flight School, and holds a BA in Marketing/Business from Iowa University.
"MedX has realized the importance and potential huge impact on revenues that are possible in the international markets, and I am pleased to be joining the MedX team at this critical stage of the company's development, " said Mr. Petersen.
About MedX Health Corp.
MedX is a leading North American developer and manufacturer of phototherapy medical devices, including dental, rehabilitation and wound care products. MedX plans to use the proceeds from its recent public offering to expand its distribution network; support its marketing program; continue development of new dental, rehabilitation and wound care products; undertake research and development for wound care products; and for working capital purposes. In particular, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its "Photobandage", a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development, marketing and sales.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this press release.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
%SEDAR: 00017466E